Racquel Bracken - 03 Feb 2023 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
/s/ Adam M. Veness, as attorney-in-fact for Racquel Bracken
Issuer symbol
N/A
Transactions as of
03 Feb 2023
Net transactions value
$0
Form type
4
Filing time
07 Feb 2023, 15:42:27 UTC
Previous filing
24 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Stock Option (Right to Buy) Award $0 +14,150 $0.000000 14,150 03 Feb 2023 Common Stock 14,150 $1.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney